Mayo researchers patent compounds that might treat schizophrenia and Parkinson’s disease 
Author Message
 Mayo researchers patent compounds that might treat schizophrenia and Parkinson’s disease

Mayo researchers patent compounds that might treat schizophrenia and Parkinsons
disease

JACKSONVILLE, Fla., May 9, 2001 -- The United States Patent Office has issued a
patent to Mayo Foundation for Medical Education and Research for a new amino
acid that may be useful in the treatment of schizophrenia and Parkinsons
disease. The amino acid, called neo-tryptophan, was created by a team of Mayo
researchers led by Elliott Richelson, M.D.; Yuan-Ping Pang, Ph.D.; and Daniel
McCormick, Ph.D. Other co-inventors on the patent are Mona Boules, Ph.D.; Abdul
Fauq, Ph.D.; Beth McMahon, Ph.D.; and Bernadette Cusack. The patent covers the
amino acid and any peptide that contains it.

Since the early 1980s scientists have suspected that neurotensin, a peptide
comprised of 13 amino acids that is present in the brain, is a natural
anti-psychotic. About 15 years ago, Dr. Richelson, a psychiatrist and
neuropsychopharmacologist, became intrigued with the idea of developing
neurotensin-like compounds as possible novel anti-psychotic {*filter*}. When
introduced into the brain, these neurotensin analogs would activate neurotensin
receptors. Unlike neurotensin itself, these analogs would not be as susceptible
to enzymatic degradation and would therefore have longer-lasting effects.

Richelson and his colleagues began to change systematically the sequence of the
8-13 amino acid portion of the molecule. In the process of developing about 80
different neurotensin 8-13 analogs, they discovered some features of the
molecule conferred better activity at a human neurotensin receptor than at a rat
receptor. Specifically, they figured out the structure of a substitute for the
tyrosine in the 11th position of the molecule that would fit better into the
human receptor. They created an amino acid similar to tryptophan that had the
right three-dimensional configuration to replace the tyrosine. Dubbed
neo-tryptophan, this new amino acid, when it was substituted into the peptide,
markedly increased binding of the peptide to the human receptor.

As a clinician, I know there is a definite need for new {*filter*} to treat
schizophrenia or Parkinsons disease, says Dr. Richelson. So, we are working
hard to get where we can test whether one of our compounds has clinical
usefulness.

Dr. Richelson is seeking cooking.net">food and Drug Administration (FDA) approval to begin
testing a neo-tryptophan containing peptide as a drug for treating schizophrenia
and Parkinsons disease. He says this peptide also has analgesic properties and
lowers body temperature, so researchers are interested in testing them to
preserve neurons in the brain after an anoxic event such as cardiac arrest. He
hopes clinical trials in human control subjects may be underway by the end of
the year.

-30-



Mon, 22 Nov 2004 03:38:01 GMT
 
 [ 1 post ] 

 Relevant Pages 

1. Mayo researchers patent compounds that might treat schizophrenia and Parkinson’s disease

2. Vertex Receives Patent for VX-497, Novel Compound to Treat Autoimmune Diseases and Hepatitis C

3. schizophrenia : Recent News. what is schizophrenia,schizophrenia treatment,treating schizophrenia in mexico,schizophrenia cause,schizophrenia diaries

4. Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma

5. Mayo Clinic Cancer Center Researcher Finds Mold By-product Chaetocin Kills Multiple Myeloma

6. Researchers: looking for new compounds?

7. FYI: Chemical May Be Key to Parkinson's Disease, Schizophrenia etc

8. Researchers can now be sued for patent infringement

9. Researchers develop first potential schizophrenia genetic animal model

10. New Amino Acid May Treat Schizophrenia


 
Powered by phpBB® Forum Software